Intralinks? Holdings, Inc. (NYSE: IL), a leading, global SaaS provider of inter-enterprise content management and collaboration solutions, and IRB Services? (Institutional Review Board Services), a leading, global provider of research ethics review and related services for the clinical research and behavioral science industries, striving for excellence in human research participant protection, today announced that the IRB Services team has selected Intralinks VIA? to support all of its secure beyond the firewall collaboration needs.
Intralinks
® Holdings, Inc. (NYSE: IL), a global SaaS provider of inter-enterprise content management and collaboration solutions, and
IRB Services
™ (Institutional Review Board Services), a global provider of research ethics review and related services for the clinical research and behavioral science industries, striving for excellence in human research participant protection, today announced that the IRB Services team has selected Intralinks VIA™ to support all of its secure beyond the firewall collaboration needs.
One of the largest institutional review boards in North America, IRB Services independently reviews, monitors and provides oversight of biomedical and behavioral research involving humans, working with many of the largest pharmaceutical and clinical research organizations (CROs), including many of the world’s most respected and recognized brands. IRB Services will be the first central institutional review board to license Intralinks VIA to facilitate the transfer of sensitive documents that are required during the approval process that every large pharmaceutical company (sponsor) or CRO must go through. This approval process happens during all phases of research in a clinical trial’s lifecycle and is essential to the commencement of a new or ongoing project.
“More and more clients have been requesting secure portals to help with the exchange of regulatory documents required during the clinical trial process,” said Simon A. Corman, director, Business Operations at IRB Services. “Our team is excited to use Intralinks VIA to facilitate this process. We looked at many collaborative solutions, but only Intralinks provides the security and ease-of-use we need. Further, as the first central IRB to implement the Intralinks VIA solution, we will be able to leverage the existing widespread Intralinks user base to maximize efficiencies and further solidify our position as a market leader. Utilizing a collaboration platform that we can trust with sensitive information around clinical trials on a global scale will help bolster our services in the eyes of our clients and accelerate the clinical trial process, which is always a plus.”
Intralinks provides breakthrough collaboration solutions that give demanding professionals the freedom to work confidently beyond traditional boundaries. Intralinks VIA is an elegantly simple enterprise collaboration solution that makes it easy for anyone to sync, share and UNshare™ files, work efficiently on group projects, and manage content wherever it goes – all with robust security and strong control capabilities. Used by over 99 percent of the global Fortune 1000, Intralinks’ solutions go beyond just file sharing to ensure that productive work gets done, while protecting that work wherever it goes.
“IRB Services works with virtually all of the big pharmaceutical companies, CROs and research sites, and adding Intralinks VIA will only make IRB Services more competitive,” said Douglas Gordon, senior vice president, product marketing at Intralinks. “As a market leader in ethics review services, we are proud IRB Services selected Intralinks to support its collaboration needs.”
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
FDA-Approved Gene Therapy Beqvez Shows Sustained Efficacy, Safety in Long-Term Hemophilia B Trial
April 17th 2025Beqvez (fidanacogene elaparvovec), an FDA-approved one-time gene therapy for hemophilia B, demonstrated sustained factor IX expression, low bleeding rates, and a favorable safety profile over long-term follow-up.